Clinical and immunohistochemical study of the effect of a cosmetic product in patients with asteatotic eczema.
Cutaneous xerosis is a common clinical condition associated with an altered barrier function of the stratum corneum. Xerotic skin appears dry, rough and slightly scaling. Patients complain of pruritus and stinging. Our aim was to investigate the clinical effects of a cosmetic ointment (Scherilan) in patients with circumscribed senile xerosis (also called asteatotic eczema). Moreover, variations in expression of epidermal proteins such as keratin (K)-5 and involucrin, detected by immunohistochemistry, were also evaluated before and after topical treatment. We enrolled 30 patients (11 males, 19 females) with asteatotic eczema. We examined dryness, roughness and desquamation and symptoms such as itching and dryness. A score of 0 to 3 was assigned to each of these parameters. A biopsy was performed in seven patients before and after a 21-day topical treatment. All skin specimens were then immunostained with antibodies to K5 and involucrin. At day 7 or 21 of treatment all signs of xerosis and pruritus were significantly reduced; furthermore, the reduction increased with the duration of therapy. Before treatment K5 was strongly expressed in stratum basale (SB) and stratum spinosum (SS), while involucrin was strongly expressed in stratum granulosum (SG) and the upper portion of SS. In contrast, after treatment immunostaining for K5 was restricted to SB and the lower part of SS, while involucrin showed intense staining in SG. We highlight the importance of treating cutaneous xerosis with an ointment such as this one, which probably induces an increase of lipid content of the SC intercellular matrix.
Caproni
M
M
Department of Dermatological Sciences, University of Florence, Italy.
Torchia
D
D
Pestelli
E
E
Volpi
W
W
Fabbri
P
P
Schincaglia
E
E
D000368:Aged; D001706:Biopsy; D049109:Cell Proliferation; D003358:Cosmetics; D004485:Eczema / Q000188:drug therapy*; D004817:Epidermis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D006016:Glycolates / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D053555:Keratin-5; D007633:Keratins / Q000096:biosynthesis; D050356:Lipid Metabolism; D008055:Lipids / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009824:Ointments / Q000627:therapeutic use*; D011498:Protein Precursors / Q000096:biosynthesis; D011537:Pruritus; D012871:Skin Diseases / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014810:Vitamin E / Q000494:pharmacology*
D003358:Cosmetics; D006016:Glycolates; C503940:KRT5 protein, human; D053555:Keratin-5; D008055:Lipids; D009824:Ointments; D011498:Protein Precursors; C503437:Scherilan; D014810:Vitamin E; C032253:involucrin; D007633:Keratins